Janssen Search
Search results
Pushing Back the Threat of Influenza
Pushing Back the Threat of Influenza: Reflecting on the WHO Global Influenza Strategy The publication of the World Health Organization (WHO)’s new Global Influenza Strategy gives us pause to reflect on where we currently stand in the fight against ...
Building Equitable Access For Patients With Lung Cancer
Building Equitable Access to Next-Generation Sequencing and Targeted Therapies for All Patients With Lung Cancer The cancer research landscape looked vastly different when I began my career almost 15 years ago. As just one example, when I graduated from ...
Earth Day 2017
Why Janssen Cares About the Environment April 22, 2017 will mark the 47th annual celebration of Earth Day. To recognize Earth Day 2017, we sat down with Philip Dahlin, Global Director, Sustainability, at Janssen to learn more about the efforts of ...
Taking action together to tackle TB
Taking Action Together to Tackle TB A week is a long time in politics, so the saying goes. In that case, 135 years must be an eternity in healthcare. On March 24, 1882, German physician Robert Koch presented a paper at a medical conference which ...
European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Aug 04, 2022 Belgium Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL BEERSE, BELGIUM, 4 August 2022 – The Janssen Pharmaceutical Companies of Johnson ...
Clinical Trial Diversity
Clinical Trial Diversity: Putting Thought to Action to Develop Sustainable Improvements The lack of diversity in clinical trials has been recognized as a major impediment to healthcare equality for decades. Unfortunately, attempts to increase ...
Empowering Black Americans for Greater Clinical Trial Representation
Empowering Black Americans for Greater Clinical Trial Representation In honor of Black History Month, Janssen is spotlighting its commitment to increase diversity among its clinical trial participants, and to expand community engagement to build ...
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Dec 09, 2022 United States RARITAN, N.J., December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...
Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
Apr 21, 2023 United States Click to Access Audio Press Release Important new data on Janssen’s investigational gene therapy portfolio, including botaretigene sparoparvovec (bota-vec) and JNJ-1887, will be presented RARITAN, N.J., April 21, 2023 – The ...
Commitment to Immunodermatology Newsroom
Welcome to the Janssen Immunodermatology Newsroom! Below, please find the latest data, content, meeting news and leadership messages about our progress and commitment to developing transformational approaches and innovative medicines for diseases like ...